Clinical trials: Semaglutide, open to volunteers
Obesity, Menopause
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications.
- Trial name
- NCT07057310
- Testing
- semaglutide or tirzepatide, Lifestyle modification intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Cannabis Use Disorder, Cue-reactivity
Semaglutide for the Treatment of Cannabis Use Disorder
The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder. The main questions it aims to answer are: 1.
- Trial name
- S-CUD (NCT07879612)
- Testing
- semaglutide
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with…
- Trial name
- MARITIME-T2D-3 (NCT07866066)
- Testing
- Maridebart cafraglutide, Semaglutide
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,300 people
- Sponsor
- Amgen
Bipolar I Disorder, Bipolar II Disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity
- Trial name
- OBOE-Mayo (NCT07213466)
- Testing
- Group Therapy Program, semaglutide, Phentermine-Topiramate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Diabetes Mellitus, Type 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide.
- Trial name
- NCT07415954
- Testing
- NNC0662-0419, Semaglutide
- Where
- 63 sites in United States, Croatia and 8 more
- Volunteers
- 270 people
- Sponsor
- Novo Nordisk A/S
Obesity, Interstitial Lung Disease
Feasibility of Semaglutide in Advanced Lung Disease
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: 1.
- Conditions
- Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary
- Trial name
- NCT05746039
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Type 2 Diabetes
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite GLP-1-based therapy.
- Trial name
- NCT07502508
- Testing
- icovamenib 100 mg
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biomea Fusion Inc.
Kidney Transplant Recipient
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).
- Trial name
- SPOT-DM (NCT06913023)
- Testing
- Semaglutide 0.25 mg, Semaglutide 0.5 mg, Semaglutide 1.0 mg
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- University Health Network, Toronto
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- ADIPO-CKD (NCT07309094)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor, Tirzepatide
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Cardenal Herrera University
Obesity; Drug
Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake.
- Trial name
- NCT06856928
- Testing
- Meal Challenge
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Prediabetes / Type 2 Diabetes
A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
This is a randomized, single-blind, controlled, parallel clinical trial to examine the efficacy and safety of AMPK Charge+® with and without use of semaglutide on glycemic response in adults with prediabetes or Type 2 Diabetes.
- Trial name
- NCT07195994
- Testing
- AMPK Charge+®, AMPK Charge+® with semaglutide
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- QuickSilver Scientific
Alzheimer Disease, Mild Cognitive Impairment
COMMETS- Combination MCI Metabolic Syndrome
The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome
- Trial name
- NCT06072963
- Testing
- Semaglutide, Intranasal insulin
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Rutgers, The State University of New Jersey
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities.
- Trial name
- NCT07169136
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism
- Trial name
- MAINTAIN (NCT06734312)
- Testing
- Gastric Fundal Mucosal Ablation (GFMA)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dr. Christopher McGowan
Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes…
- Trial name
- NCT06717698
- Testing
- NNC0519-0130, Semaglutide
- Where
- 147 sites in United States, Argentina and 12 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss…
- Trial name
- RESTORE (NCT05819853)
- Testing
- Semaglutide Injectable Product (Wegovy and/or Ozempic)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Colorado, Denver
Foot Ulcer Due to Type 2 Diabetes Mellitus
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
The aim of this exploratory pilot study is to investigate the effect of semaglutide compared to placebo on healing of foot ulcers in type 2 diabetes patients.
- Trial name
- SEMAFOOT2 (NCT07581145)
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Ole Lander Svendsen
Obesity
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy.
- Trial name
- NCT07633639
- Testing
- LSG-Semaglutide group, LSG-Mazdutide group, LSG-Tirzepatide group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- China-Japan Friendship Hospital
Facial Skin Aging, Facial Volume Loss
Comparing Facial Aging Between Identical Twins With 3D Imaging
Identical twins share the same genes, which makes them a powerful way to study how lifestyle and environment - rather than genetics - affect how faces age.
- Conditions
- Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
- Trial name
- NCT07760532
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ponsky Facial Aesthetics And Plastic Surgery, Llc
Obesity in Diabetes, Obesity/Therapy
Semaglutide Treatment in Type 1 Diabetes
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic…
- Conditions
- Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance
- Trial name
- OBES1TY (NCT06909006)
- Testing
- Semaglutide 2.4mg
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Nordsjaellands Hospital